Differences between Non Hodgkin Lymphoma and classic Hodgkin's Lymphoma

LymphomaNovember 6, 2026Written by Navis AI

Key Differences Between Non-Hodgkin Lymphoma and Classic Hodgkin Lymphoma

While both are cancers of the lymphatic system, Non-Hodgkin lymphoma (NHL) and classic Hodgkin lymphoma (cHL) differ significantly in their biology, behavior, and treatment approaches.

1. Cell Type & Appearance Under the Microscope

Classic Hodgkin Lymphoma:

  • Contains distinctive Reed-Sternberg (RS) cells or Hodgkin cells - large, abnormal cells that are the hallmark of this disease
  • These cells are typically CD30+, CD15+, and PAX5+ (weak), but CD20-negative in most cases
  • RS cells make up only a small portion of the tumor; most of the mass consists of normal immune cells surrounding them
  • According to NCCN Guidelines, cHL has four subtypes: nodular sclerosis, mixed cellularity, lymphocyte-rich, and lymphocyte-depleted

Non-Hodgkin Lymphoma:

  • Does NOT contain Reed-Sternberg cells
  • Consists of abnormal lymphocytes (B-cells or T-cells) that have become cancerous
  • The tumor is primarily made up of the cancer cells themselves
  • Includes over 60 different subtypes, such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and marginal zone lymphomas

Tell us what’s going on with lymphoma. 2 free answers, then a free account.

2. How They Spread

Classic Hodgkin Lymphoma:

  • Typically spreads in a predictable, orderly pattern from one lymph node group to adjacent (neighboring) groups
  • Usually starts in the upper body (neck, chest, underarms)
  • Spreads in a more "step-by-step" fashion through the lymphatic system

Non-Hodgkin Lymphoma:

  • Spreads in a random, unpredictable pattern
  • Can "skip" lymph node regions
  • More likely to involve areas outside lymph nodes (extranodal sites) like the stomach, intestines, or bone marrow at diagnosis

3. Age & Demographics

Classic Hodgkin Lymphoma:

  • Has a bimodal age distribution - two peak ages of occurrence:
    • Young adults (ages 20-30)
    • Older adults (over 55)
  • Less common overall (about 8,000 new cases annually in the U.S.)

Non-Hodgkin Lymphoma:

  • Risk increases steadily with age
  • More common in people over 60
  • Much more common overall (about 80,000+ new cases annually in the U.S.)

4. Treatment Approaches

Classic Hodgkin Lymphoma:

  • Often treated with combined modality therapy: chemotherapy plus radiation therapy
  • Common regimens include ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine)
  • According to NCCN Guidelines, treatment is highly tailored based on stage and risk factors (favorable vs. unfavorable disease)
  • Generally has excellent cure rates, especially in early stages

Non-Hodgkin Lymphoma:

  • Treatment varies widely depending on the specific subtype
  • Many subtypes use chemoimmunotherapy (chemotherapy combined with monoclonal antibodies like rituximab)
  • Some indolent (slow-growing) types may use "watch and wait" initially
  • Aggressive types often require intensive chemotherapy regimens like R-CHOP

5. Prognosis

Classic Hodgkin Lymphoma:

  • Generally has very favorable outcomes, particularly in younger patients
  • Early-stage disease has cure rates exceeding 90%
  • Even advanced-stage disease is often curable

Non-Hodgkin Lymphoma:

  • Prognosis varies dramatically by subtype:
    • Indolent (slow-growing) types like follicular lymphoma: may not be curable but patients often live many years with treatment
    • Aggressive types like DLBCL: potentially curable with intensive treatment, but require prompt therapy

6. Staging Considerations

Both use the Lugano Classification staging system (stages I-IV), but according to NCCN Guidelines:

Classic Hodgkin Lymphoma:

  • Stage is a major driver of treatment decisions
  • Divided into "favorable," "unfavorable," and "advanced" disease based on multiple factors including:
    • Bulky disease (large tumor masses)
    • Number of lymph node regions involved
    • Presence of B symptoms (fevers, night sweats, weight loss)
    • Elevated inflammatory markers (ESR)

Non-Hodgkin Lymphoma:

  • Stage is important but the specific subtype often matters more for treatment decisions
  • Many patients present with advanced-stage disease at diagnosis
  • Other factors like the International Prognostic Index (IPI) score help guide treatment intensity

Bottom Line

The key distinguishing feature is the presence of Reed-Sternberg cells in classic Hodgkin lymphoma, which are absent in NHL. This fundamental difference in cell biology leads to different spreading patterns, treatment approaches, and outcomes. Classic Hodgkin lymphoma generally has more predictable behavior and excellent cure rates, while Non-Hodgkin lymphoma encompasses a diverse group of diseases with varying behaviors and prognoses.

Questions to ask your care team:

  1. Which specific type of lymphoma do I have, and what are its unique characteristics?
  2. How does my specific subtype typically behave and respond to treatment?
  3. What does my pathology report show about the cell markers (like CD20, CD30, CD15)?
  4. Based on my type, what are the most effective treatment options?

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.

Your next question, already answered

Tap to keep going. 2 free answers, then a free account.

Ask Navis about your case

That answer is general. Ask about your specific situation. Answered right here.

For informational purposes only

This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.

Sources & medical oversight

Facing this with someone you love?

Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.

Start a care circle →

More questions about Lymphoma